The 15 references in paper Jin-Ping Zheng, Fu-Qiang Wen, Chun-Xue Bai, Huan-Ying Wan, Jian Kang, Ping Chen, Wan-Zhen Yao, Li-jun Ma, Xia Li, Luca Raiteri, Marco Sardina, Yi Gao, Bai-Song Wang, Nan-Shan Zhong, Дж.-П. Женг, Ф.-К. Вен, Ч.-К. Бей, Х.-Я. Ван, Дж. Канг, П. Чен, В.-Ж. Яао, Л.-Дж. Ма, К. Ли, Д. Райтери, М. Сардина, И. Гао, Б.-С. Ванг, Н.-Ш. Зонг (2014) “РАНДОМИЗИРОВАННОЕ ДВОЙНОЕ СЛЕПОЕ ПЛАЦЕБО-КОНТРОЛИРУЕМОЕ ИССЛЕДОВАНИЕ PANTHEON: ПРИМЕНЕНИЕ N-АЦЕТИЛЦИСТЕИНА В ДОЗЕ 600 МГ 2 РАЗА В ДЕНЬ ПРИ ОБОСТРЕНИЯХ ХРОНИЧЕСКОЙ ОБСТРУКТИВНОЙ БОЛЕЗНИ ЛЕГКИХ // TWICE DAILY N-ACETYLCYSTEINE 600 MG FOR EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (PANTHEON): A RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL” / spz:neicon:pulmonology:y:2014:i:3:p:86-98

1
Vestbo J., Hurd S.S., Agusti A.G. et al.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2013; 187: 347–365.
(check this in PDF content)
2
Donaldson G.C., Seemungal T.A., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002; 57: 847–852.
(check this in PDF content)
3
Spencer S., Calverley P.M., Burge P.S., Jones P.W. Impact of preventing exacerbations on deterioration of health status in COPD. Eur. Respir. J. 2004; 23: 698–702.
(check this in PDF content)
4
Wouters E.F. The burden of COPD in The Netherlands: results from the confronting COPD survey. Respir. Med. 2003; 97 (Suppl. C): S51–59.
(check this in PDF content)
5
Blackwell T.S., Blackwell T.R., Holden E.P. et al.In vivo antioxidant treatment suppresses nuclear factor–kappa B activation and neutrophilic lung infl ammation. J. Immunol. 1996; 157: 1630–1637.
(check this in PDF content)
6
Overveld F.J., Demkow U., Gorecka D. et al.New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine. J. Physiol. Pharmacol. 2005; 56 (Suppl. 4): 135–142.
(check this in PDF content)
7
Dekhuijzen P.N.R.Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur. Respir. J. 2004; 23: 629–636.
(check this in PDF content)
8
Ueno T., Yamada M., Igarashi Y., Ogawa T. N-acetyl cysteine protects osteoblastic function from oxidative stress. J. Biomed. Mater. Res. A. 2011; 99: 523–531.
(check this in PDF content)
9
Sadowska A.M., Manuel-Y-Keenoy B., De Backer W.A. Antioxidant and anti-infl ammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo doseeffects: a review. Pulm. Pharmacol. Ther. 2007; 20: 9–22.
(check this in PDF content)
10
Grandjean E.M., Berthet P., Ruffmann R., Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebocontrolled clinical trials. Clin. Ther. 2000; 22: 209–221.
(check this in PDF content)
11
Gerrits C.M., Herings R.M., Leufkens H.G., Lammers J.W. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 795–798.
(check this in PDF content)
12
Decramer M., Rutten-van Molken M., Dekhuijzen P.N. et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomised on N-acetylcysteine Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005; 365: 1552–1560.
(check this in PDF content)
13
Schermer T., Chavannes N., Dekhuijzen R. et al. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir. Med. 2009; 103: 542–551.
(check this in PDF content)
14
Zuin R., Palamidese A., Negrin R. et al. High dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin. Drug Investig. 2005; 25: 401–408.
(check this in PDF content)
15
Zheng J.P., Wen F.Q., Bai C.X. et al. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study. COPD. 2013; 10:
(check this in PDF content)